At a glance
ClinicalIndex Comparison RecordN/ACompleted· 100 enrolled
Drug / intervention
PCR (Polymerase Chain Reaction) targeting the 16 ribosomal DNAother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Role of Polymerase Chain Reaction in the Management of Patients With Infective Endocarditis: Modern Diagnostic and Therapeutic Concepts
Fondazione Policlinico Universitario Agostino Gemelli IRCCS·interventional·Posted Mar 30, 2023·Updated Aug 15, 2025
In Brief
A clinical study evaluating PCR (Polymerase Chain Reaction) targeting the 16 ribosomal DNA for Endocarditis Infective. Completed, enrolled 100 participants across 2 sites.
Detailed Summary
The aim of this study is to prospectively investigate the additional diagnostic value of broad range PCR targeting the 16 ribosomal DNA in diagnosis and management of patients with infective endocarditis who are candidate for surgicaltherapy;
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndocarditis Infective
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartApr 2020
First PostedMar 2023
Primary CompletionMay 2024
Study CompletionOct 2024
TodayJul 2026
First PostedMar 30, 2023
Enrollment StartApr 1, 2020
Primary CompletionMay 31, 2024
Study CompletionOct 31, 2024
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 3.3 years ago
Interventions
PCR (Polymerase Chain Reaction) targeting the 16 ribosomal DNAother
Molecular diagnostic using a broad range PCR on obtained histological material (native valve/valve prosthesis/fragments of them)